Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)
NCT06806930
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to determine how the duration of hormone blocking (endocrine) therapy given prior to surgery (called "neoadjuvant" treatment) affects breast cancer. The main questions the trial aims is answer are: How breast cancer responds to endocrine therapy given prior to surgery? To predict tumor pre-operative endocrine prognostic index (PEPI) score for subjects enrolled in cohort B or C Participants with early-stage breast cancer (Stage I-III) who are eligible for Neoadjuvant Endocrine Therapy (NET) will be enrolled in the study.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer Stage I
- Breast Cancer Stage II
- Breast Cancer Stage III
- Carcinoma, Breast
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- George Washington University
- Last updated on ClinicalTrials.gov
- March 3, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
District of Columbia · 1
- George Washington-Medical Faculty Associates · Washington D.C., DC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.